These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 30513009)

  • 1. An update on ketamine and its two enantiomers as rapid-acting antidepressants.
    Zhang K; Hashimoto K
    Expert Rev Neurother; 2019 Jan; 19(1):83-92. PubMed ID: 30513009
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K
    Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
    Hashimoto K
    Biochem Pharmacol; 2020 Jul; 177():113935. PubMed ID: 32224141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A historical review of antidepressant effects of ketamine and its enantiomers.
    Wei Y; Chang L; Hashimoto K
    Pharmacol Biochem Behav; 2020 Mar; 190():172870. PubMed ID: 32035078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arketamine, a new rapid-acting antidepressant: A historical review and future directions.
    Zhang JC; Yao W; Hashimoto K
    Neuropharmacology; 2022 Nov; 218():109219. PubMed ID: 35977629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice.
    Yamaguchi JI; Toki H; Qu Y; Yang C; Koike H; Hashimoto K; Mizuno-Yasuhira A; Chaki S
    Neuropsychopharmacology; 2018 Aug; 43(9):1900-1907. PubMed ID: 29802366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.
    Wei Y; Chang L; Hashimoto K
    Mol Psychiatry; 2022 Jan; 27(1):559-573. PubMed ID: 33963284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
    Yokoyama R; Higuchi M; Tanabe W; Tsukada S; Naito M; Yamaguchi T; Chen L; Kasai A; Seiriki K; Nakazawa T; Nakagawa S; Hashimoto K; Hashimoto H; Ago Y
    Pharmacol Biochem Behav; 2020 Apr; 191():172876. PubMed ID: 32088360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbiota is involved in the antidepressant-like effect of (S)-norketamine in an inflammation model of depression.
    Wang Y; Jiang R; Wu Z; Zhou L; Xu J; Huang C; Yang L; Zhu B; Yan E; Liu C; Yang C
    Pharmacol Biochem Behav; 2021 Aug; 207():173226. PubMed ID: 34217782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arketamine for cognitive impairment in psychiatric disorders.
    Hashimoto K
    Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1513-1525. PubMed ID: 36786865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine.
    Shirayama Y; Hashimoto K
    Int J Neuropsychopharmacol; 2018 Jan; 21(1):84-88. PubMed ID: 29155993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketamine: A tale of two enantiomers.
    Jelen LA; Young AH; Stone JM
    J Psychopharmacol; 2021 Feb; 35(2):109-123. PubMed ID: 33155503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketamine in neuropsychiatric disorders: an update.
    Johnston JN; Kadriu B; Kraus C; Henter ID; Zarate CA
    Neuropsychopharmacology; 2024 Jan; 49(1):23-40. PubMed ID: 37340091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of rapid antidepressant effects of Kir4.1 channel inhibitors in a chronic social defeat stress model: Comparison with (R)-ketamine.
    Xiong Z; Zhang K; Ishima T; Ren Q; Ma M; Pu Y; Chang L; Chen J; Hashimoto K
    Pharmacol Biochem Behav; 2019 Jan; 176():57-62. PubMed ID: 30502360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity.
    Nguyen TML; McGowan JC; Gardier AM
    Neuropharmacology; 2022 Mar; 206():108936. PubMed ID: 34965407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects.
    Yang C; Shirayama Y; Zhang JC; Ren Q; Yao W; Ma M; Dong C; Hashimoto K
    Transl Psychiatry; 2015 Sep; 5(9):e632. PubMed ID: 26327690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
    Zanos P; Moaddel R; Morris PJ; Georgiou P; Fischell J; Elmer GI; Alkondon M; Yuan P; Pribut HJ; Singh NS; Dossou KS; Fang Y; Huang XP; Mayo CL; Wainer IW; Albuquerque EX; Thompson SM; Thomas CJ; Zarate CA; Gould TD
    Nature; 2016 May; 533(7604):481-6. PubMed ID: 27144355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine's antidepressant action: beyond NMDA receptor inhibition.
    Hashimoto K
    Expert Opin Ther Targets; 2016 Nov; 20(11):1389-1392. PubMed ID: 27646666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.
    Molero P; Ramos-Quiroga JA; Martin-Santos R; Calvo-Sánchez E; Gutiérrez-Rojas L; Meana JJ
    CNS Drugs; 2018 May; 32(5):411-420. PubMed ID: 29736744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketamine for Depression, 3: Does Chirality Matter?
    Andrade C
    J Clin Psychiatry; 2017 Jun; 78(6):e674-e677. PubMed ID: 28682536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.